Sugi Predict

Sugi Predict / Compounds / SCHEMBL735278

SCHEMBL735278

SCHEMBL735278

O=[C]C(=O)OCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.59
▸ TDP1 Q9NUW8 2/20 0.57
▸ MAPK1 P28482 1/20 0.57
▸ L3MBTL1 Q9Y468 1/20 0.57
▸ SLC6A2 P23975 1/20 0.57
▸ SLC6A3 Q01959 1/20 0.57
▸ KMT2A Q03164 1/20 0.57
▸ LMNA P02545 3/20 0.52
▸ HCAR2 Q8TDS4 1/20 0.52
▸ P2RX4 Q99571 2/20 0.49
▸ HTT P42858 1/20 0.49
▸ P2RX1 P51575 1/20 0.47
▸ P2RX3 P56373 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ CA12 O43570 2/20 0.47
▸ CA1 P00915 2/20 0.47
▸ CA2 P00918 2/20 0.47
▸ CA9 Q16790 2/20 0.47
▸ TSHR P16473 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6572932 0.85 ALDH1A1 (0.61) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL27144 0.82 ALDH1A1 (0.68) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL446810 0.82 ALDH1A1 (0.62) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL907611 0.82 ALDH1A1 (0.57) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL1400119 0.82 ALDH1A1 (0.57) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL10919971 0.81 ALDH1A1 (0.52) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL28080744 0.80 ALDH1A1 (0.55) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL9409655 0.80 ALDH1A1 (0.55) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL7880310 0.80 ALDH1A1 (0.55) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL6881578 0.80 P2RX4 (0.48) ALDH1A1MAPK1L3MBTL1KMT2AP2RX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 460 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023143605-A1 PROCESS FOR THE SYNTHESIS OF PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS NOVARTIS AG (CH) 2023-08-03 — — WO claimed
US-10253032-B2 Spiro-lactam NMDA receptor modulators and uses thereof APTINYX INC. (US) 2019-04-09 — — US claimed
EP-2951183-B1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF APTINYX INC (US) 2019-03-13 — — EP claimed
EP-2951186-B1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF APTINYX INC (US) 2018-07-25 — — EP claimed
US-20180155354-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2018-06-07 — — US claimed
CN-104780761-A Use of substituted 2, 3-dihydro-1-benzofuran-4-carboxylic acids or salts thereof as active substances against abiotic plant stress BAYER CROPSCIENCE AG 2015-07-15 — — CN claimed
EP-1423137-B1 LIPOPEPTIDE STEREOISOMERS, METHODS FOR PREPARING SAME, AND USEFUL INTERMEDIATES CUBIST PHARM INC (US) 2009-04-29 — — EP claimed
EP-1532150-B1 NOVEL PURINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA (DE) 2008-06-11 — — EP claimed
US-7335726-B2 Lipopeptide stereoisomers, methods for preparing same and useful intermediates CUBIST PHARMACEUTICALS, INC. (US) 2008-02-26 — — US claimed
US-7262268-B2 Lipopeptide stereoisomers, methods for preparing same, and useful intermediates CUBIST PHARMACEUTICALS, INC. (US) 2007-08-28 — — US claimed
EP-0376218-B1 Racemization free attachment of amino acids to solid phase PERSEPTIVE BIOSYSTEMS INC (US) 1999-02-24 — — EP claimed
EP-0317970-B1 A process for the synthesis of amikacin GIST BROCADES ITALY (IT) 1995-07-26 — — EP claimed
EP-0583414-A4 — — 1994-03-30 — — EP claimed
EP-0583414-A1 ERYTHROMYCIN DERIVATIVES ABBOTT LABORATORIES (US) 1994-02-23 — — EP claimed
US-5187270-A Solid phase synthesis of peptides using the reaction product of an N-protected amino acid and a 2,4-dichlorophenyl (4-halo methylphenoxy)acetate; efficiency; purity; kinetics MILLIPORE CORPORATION (US) 1993-02-16 — — US claimed
WO-1992019247-A1 ERYTHROMYCIN DERIVATIVES ABBOTT LABORATORIES (US) 1992-11-12 — — WO claimed
EP-0489220-A1 Cytotoxic N,N'-bis (succinyl-peptide-) derivatives of 1,4-bis (aminoalkyl)-5,8-dihydroxyanthraquinones and antibody conjugates thereof AMERICAN CYANAMID COMPANY (US) 1992-06-10 — — EP claimed
EP-0376218-A2 Racemization free attachment of amino acids to solid phase PERSEPTIVE BIOSYSTEMS, INC. (US) 1990-07-04 — — EP claimed
EP-0295316-A2 Antitumor amino acid and peptide derivatives of 1,4-bis[ (aminoalkyl and hydroxyaminoalkyl)- amino]-5,8 dihydroxyanthraquinones AMERICAN CYANAMID COMPANY (US) 1988-12-21 — — EP claimed
EP-0113538-A2 Protein sequencing method and reagent MOLECULAR GENETICS RESEARCH & DEVELOPMENT LIMITED PARTNERSHIP (US) 1984-07-18 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10253032-B2 Spiro-lactam NMDA receptor modulators and uses thereof GRIN1, GRIN2A, GRIN3A ALDH1A1 2288/4885TDP1 4059/4885MAPK1 3557/4885
US-20180155354-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN3A ALDH1A1 2288/4885TDP1 4059/4885MAPK1 3557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.